| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,320 |
4,604 |
$684K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,440 |
3,083 |
$322K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,997 |
1,815 |
$227K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,333 |
1,258 |
$65K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
343 |
296 |
$58K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,088 |
1,023 |
$51K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
415 |
372 |
$11K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
659 |
532 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
497 |
413 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
160 |
120 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
14 |
12 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
21 |
16 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
19 |
15 |
$491.26 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
16 |
13 |
$97.02 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
52 |
41 |
$24.70 |
| 81003 |
|
152 |
107 |
$9.00 |